Tag #Gilead Science

What is the significance of lenacapavir's designation as Science's 2024 breakthrough, considering the stagnation in HIV diagnoses in recent years?

Lenacapavir, a long-acting injectable HIV prevention drug, has been named Science magazine's 2024 breakthrough of the year. Its 99.9% effectiveness in preventing HIV in clinical trials among men who have sex with men and transgender individuals, coupled with its six-month dosage, offers significant advantages over daily oral PrEP. The FDA is expected to approve it in 2025.